Intervention not reported
Discontinuation of study drug due to adverse events · unvaccinated, non‐hospitalized people with mild symptomatic COVID‐19 (WHO scale 2 to 3) at high risk for progression to severe disease
The intervention probably leads to lower discontinuation of study drug due to adverse events (moderate certainty).
1 finding from 1 review
- Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19 2023 · Cochrane Headline outcomes onlyRR 0.49 [0.3, 0.8]1 study · 2224 participantsModerate